Kestra Medical Technologies (KMTS)
Leases connected wearable defibrillator systems for patients at elevated sudden-cardiac-arrest risk.
$25.75
At close+0.63 (+2.51%)
In millions of USD, except per-share figures
| In millions | Q1 FY21Jul 2020 | Q1 FY22Jul 2021 | Q3 FY24Jan 2024 | Q4 FY24Apr 2024 | Q1 FY25Jul 2024 | Q2 FY25Oct 2024 | Q3 FY25Jan 2025 | Q4 FY25Apr 2025 | Q1 FY26Jul 2025 | Q2 FY26Oct 2025 | Q3 FY26Jan 2026 | Q4 FY26Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 8 | 10 | 13 | 15 | 15 | 17 | 19 | 23 | 25 | 29 |
| Cost of revenue | 0 | 0 | 7 | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 12 | 13 |
| Gross profit | 0 | 0 | 1 | 1 | 4 | 6 | 7 | 8 | 9 | 11 | 13 | 16 |
| 8 | 12 | 21 | 22 | 23 | 25 | 27 | 56 | 38 | 43 | 48 | 55 | |
| Research & development | 6 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 5 | 6 |
| 2 | 7 | 17 | 18 | 19 | 21 | 24 | 50 | 34 | 38 | 43 | 49 | |
| Selling & marketing | 2 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −8 | −12 | −20 | −20 | −18 | −19 | −21 | −48 | −29 | −32 | −35 | −39 |
| 0 | −1 | −2 | −2 | −2 | −1 | −1 | −3 | 3 | −1 | 1 | 1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | −2 |
| Interest expense | 0 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 1 | −5 | −1 | −3 | 0 |
| Income before tax | −8 | −13 | −22 | −22 | −20 | −21 | −22 | −51 | −26 | −33 | −34 | −39 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −8 | −13 | −22 | −22 | −20 | −21 | −22 | −51 | −26 | −33 | −34 | −39 |
| Other adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 |
| Net income | −8 | −13 | −22 | −22 | −20 | −20 | −22 | −52 | −26 | −33 | −34 | −39 |
| EPS, basic | −$0.16 | −$0.27 | −$0.47 | −$0.45 | −$0.45 | −$0.48 | −$0.50 | −$2.21 | −$0.50 | −$0.64 | −$0.61 | −$0.67 |
| EPS, diluted | −$0.16 | −$0.27 | −$0.47 | −$0.45 | −$0.45 | −$0.48 | −$0.50 | −$2.21 | −$0.50 | −$0.64 | −$0.61 | −$0.67 |
| Weighted average shares, basic | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 51 | 51 | 53 | 58 |
| Weighted average shares, diluted | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 51 | 51 | 53 | 58 |
| EBITDA | −8 | −12 | −17 | −17 | −16 | −17 | −18 | −47 | −22 | −28 | −30 | −50 |
| Depreciation & amortization | 0 | 0 | 3 | 4 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | −11 |
| EBIT | −8 | −12 | −20 | −20 | −18 | −19 | −20 | −49 | −24 | −31 | −32 | −39 |
